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Osteoblasts are the bone forming cells, capable of secreting an extracellular matrix with mineralization
potential. The exact mechanism by which osteoblasts differentiate and form a mineralized extracellular
matrix is presently not fully understood. To increase our knowledge about this process, we conducted
proteomics analysis in human immortalized preosteoblasts (SV-HFO) able to differentiate andmineralize.
We identified 381 proteins expressed during the time course of osteoblast differentiation. Gene ontology
analysis revealed an overrepresentation of protein categories established as important players for
osteoblast differentiation, bone formation, and mineralization such as pyrophosphatases. Proteins
involved in antigen presentation, energy metabolism and cytoskeleton rearrangement constitute other
overrepresented processes, whose function, albeit interesting, is not fully understood in the context of
osteoblast differentiation and bone formation. Correlation analysis, based on quantitative data, revealed
a biphasic osteoblast differentiation, encompassing a premineralization and a mineralization period.
Identified differentially expressed proteins between mineralized and nonmineralized cells include
cytoskeleton (e.g., CCT2, PLEC1, and FLNA) and extracellular matrix constituents (FN1, ANXA2, and
LGALS1) among others. FT-ICR-MS data obtained for FN1, ANXA2, and LMNA shows a specific
regulation of these proteins during the different phases of osteoblast differentiation. Taken together,
this study increases our understanding of the proteomics changes that accompany osteoblast
differentiation and may permit the discovery of novel modulators of bone formation.
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Introduction
Bone is a highly specialized form of connective tissue. It is
very dynamic, being continuously resorbed by osteoclasts and
rebuild by osteoblasts. Osteoblasts are the bone-forming cells.
They synthesize an extracellular matrix (ECM) and participate
in the mineralization of this matrix. While the majority of
osteoblasts enter apoptosis, the remainder enters the last stage
of osteoblast differentiation becoming osteocytes. The process
of osteoblast differentiation from the mesenchymal stem cell
(MSC) lineage is tightly regulated and encompasses several
steps. Expression of the osteoblasts-specific transcription fac-
tors Runx2 and Osterix is essential to drive MSCs toward the
osteoblastic lineage.1–3 After lineage commitment, several
differentiation steps take place until the formation of mature
osteoblasts. These cells are characterized by the expression of
the matrix proteins collagen type I, osteocalcin, osteopontin,
bone sialoprotein, and alkaline phosphatase (ALP), an enzyme
which is believed to be involved in bone matrix mineralization.4
In vitro, human osteoblast differentiation can be triggered by
glucocorticoids,5–7 in a process not completely understood. An
important step toward understanding osteoblast differentiation
is to characterize the osteoblast proteome during differentia-
tion. Over the last years, proteomics technology has made
tremendous progress,8,9 and nowadays, mass spectrometry
(MS)-based proteomics tools can be applied to generate not
only qualitative, but also quantitative information, to gain a
more holistic view of biological systems.8 Several proteomic
studies have been conducted to unravel the mechanisms
underlying osteogenesis.10–14 Yet only a portion of the osteo-
blast proteome has been unveiled and additional, quantitative
proteomic analyses are needed to reach the goal of capturing
the full osteoblast proteome.
In this study, we aimed to extend the knowledge about
human osteogenesis by investigating the protein expression
during the time-course of glucocorticoid-induced osteoblast
differentiation and mineralization (differentiating osteoblasts).
For this purpose, we used the well-characterized preosteoblast
cell line SV-HFO15 that develops into mature osteoblasts in a
3-week time period in the presence of glucocorticoids.5 Two
mass spectrometry platforms were used for purposes of
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identification (nano-LC-MS/MS using an LTQ-Orbitrap) and
quantification (MALDI-FT-ICR-MS). Using nano-LC-MS/MS,
we focused on the identification of proteins expressed by
differentiating osteoblasts. Moreover, quantitative peptide data
was obtained by MALDI-FT-ICR-MS and complemented with
specific data-dependent peptide/protein identification by nano-
LC-MS/MS.16
Materials and Methods
Cell Culture. Human SV-HFO cells were seeded in a density
of 5 × 103 vital cells/cm2 and precultured for 1 week in R-MEM
(GIBCO, Paisley, U.K.) supplemented with 20 mM HEPES, pH
7.5 (Sigma, St. Louis, MO), streptomycin/penicillin, 1.8 mM
CaCl2 (Sigma), and 10% heat-inactivated FCS (GIBCO) at 37 °C
and 5% CO2 in a humidified atmosphere. During preculture,
cells remained in an undifferentiated stage. At this point, cells
were seeded in a density of 1 × 104 vital cells/cm2 in the
presence of 2% charcoal-treated FCS. For induction of osteo-
blast differentiation and mineralization, the basal medium was
freshly supplemented with 10 mM -glycerophosphate (Sigma)
and 100 nM dexamethasone (Sigma). For the nondifferentiating
osteoblasts, the culture condition was identical except for the
presence of dexamethasone. Throughout the remainder of the
study, DEX-treated and non-DEX-treated cultures are referred
as differentiating and nondifferentiating osteoblasts, respec-
tively. The media was replaced every 2-3 days in both
nondifferentiating and differentiating osteoblasts.
Alkaline Phosphatase. ALP activity was assayed by deter-
mining the release of paranitrophenol from paranitrophe-
nylphosphate (20 mM diethanolamine buffer supplemented
with 1 mM MgCl2 at pH 9.8) in the SV-HFO lysates for 10 min
at 37 °C. Adding 0.06 M NaOH stopped the reaction. Adsorption
was measured at 405 nm. Results were corrected for the DNA
content of the cell lysates.
Mineralization. For quantification of the mineral content,
cell lysates were incubated overnight in 0.24 M HCl at 4 °C.
Calcium content was colorimetrically determined with a cal-
cium assay kit (Sigma) according to the manufacturer’s instruc-
tions. Results were corrected for the DNA content of the cell
lysates. For Alizarin Red staining, cell cultures were fixed for
60 min with 70% ethanol on ice. After fixation, cells were
washed twice with PBS and stained for 10 min with Alizarin
Red solution (saturated Alizarin Red in demineralized water
was titrated to pH 4.2 using 0.5% ammonium hydroxide).
Protein Isolation. At day 5, 10, and 19 of culture, nondif-
ferentiating and differentiating cells, in three biological repli-
cates (a total of 18 samples), were washed in phosphate-
buffered saline (PBS, GIBCO) and lysed directly in a culture
dish by adding TRIzol (Invitrogen, Carlsbad, CA). The protein
phenol-ethanol phase was stored at -80 °C. Proteins were
precipitated using methanol/chloroform.17 To facilitate protein
solubilization and enzymatic cleavage of proteins, pellets were
resuspended in 100 µL of 0.1% (w/v) RapiGest SF (Waters,
Milford, MA) in 50 mM ammonium bicarbonate and dissolved
by sonification at 70% amplitude and maximum temperature
of 18 °C (Bransons Ultrasonics, Danbury, CT) until no ag-
gregates were visible. Protein concentration was determined
using a BCA kit (Pierce Biotechnology, Rockford, IL). For
digestion, 0.1 mg/mL of trypsin gold, MS grade (Promega,
Madison, WI) reconstituted in 50 mM acetic acid was added
to each sample, at a 1:50 (w/w) ratio. After overnight incubation
at 37 °C, 10% trifluoracetic acid (TFA) was added to the digested
protein samples in order to stop the enzymatic reaction and
remove Rapigest hydrolytic byproduct (final TFA concentration
0.5%, pH < 2). Finally, samples were aliquoted and stored at
-80 °C until use for LC-MS/MS and MALDI-FT-ICR-MS.
LC-MS/MS. One microliter of protein sample was injected
onto a nanoLC system (Dionex, Amsterdam, The Netherlands)
and trapped for 7.5 min on a C18 PepMap 100 column (5 mm
×300 µm i.d., Dionex, Sunnyvale, CA). Fractionation was
performed using a C18 PepMap 100 column (150 mm ×75 µm,
3 µm, 100 Å, Dionex, Sunnyvale, CA) using a 80 min gradient
running from 0-50% of buffer A (80% acetonitrile (ACN), 20%
H2O, 0.1% TFA) in buffer B (100% H2O, 0.1% TFA), followed by
a 23.5 min gradient to 100% B at 250 nL/min (Dionex). A UV
detector (214 nm) was used to monitor the separation. The
nanoLC was coupled to a LTQ-Orbitrap (Thermo Fisher
Scientific, Bremen, Germany). Mass spectrometry data was
acquired in both data-independent and dependent mode, the
latter to include those peptide masses found to be differentially
expressed by MALDI-FT-ICR-MSmeasurements (see below) for
specific sequencing. This preselection of data results in an
increased chance to identify the peptides of interest than just
by default data independent measurements. The mass toler-
ance of the selected inclusion list was 10 ppm.
Fragmentation spectra were searched against the Human
International Protein Index (IPI) database v3.18 (June 13, 2006)
with SEQUEST using the Bioworks software (Version 3.3,
Thermo Electron, San Jose, CA). The mass accuracy for the
database was set to 5 ppm for the precursor ions and 1 Da for
the fragment ions. Only peptides with a probability less than
0.001 and meeting the SEQUEST HUPO PPP high confidence
parameters18,19 were considered for further analysis.
Peptides masses within a mass window of 7 ppm to LC-MS/
MS and 2 ppm to the FT-ICR-MS (see section below) measure-
ments were considered as identified. To verify isoform speci-
ficity and eliminate redundant protein identifications, the
peptides were searched against the same IPI Human database
using Standalone Blast (Basic Local Alignment Search Tool)
software version 2.2.17 with the PAM30 scoring matrix for short
amino acid sequences. Sequence coverage determination was
performed using the Protein Coverage Summarizer v1.2.3064
tool, freely available in the PNNL/OMICS.PNNL.GOV Web site
(http://omics.pnl.gov/software/ProteinCoverageSummarizer.
php).
Bioinformatic Gene Ontology Analysis. Proteins identified
in the normal scan mode by LC-MS/MS were analyzed using
Ingenuity Pathway Analysis (version 7.60) and DAVID Bioin-
formaticsResourcesv6.7(http://david.abcc.ncifcrf.gov/home.jsp)20,21
to obtain a comprehensive description of the overrepresented
biological processes and functional related groups of proteins
within our data set. For DAVID analysis, only Bonferroni
significant (p-value < 0.001) overrepresented terms, containing
more than 9 proteins, were considered. As background, the
default Homo sapiens genome was used.
MALDI-FT-ICR-MS. Half microliter of protein sample was
mixed with a 2,5-dihydroxy benzoic acid (DHB, Bruker Dal-
tonics, Bremen, Germany) matrix solution (10 mg/mL in 0.1%
TFA/water) in a 1:1 (v/v) ratio, spotted onto a 600/384 Anchor-
Chip target plate (Bruker Daltonics) in duplicate, and allowed
to dry at room temperature. MALDI-FTICR MS measurements
were performed in a Bruker Apex-Q equipped with a 9.4 T
magnet (Bruker Daltonics). For each measurement, scans of
10 shots at 75% laser power were accumulated. Mass spectra
were acquired in the mass range of 800-4000 Da and processed
with a Gaussian filter and 2 zero fillings. To ensure good mass
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accuracy, an external calibration was performed using a Peptide
Calibration Standard II (Bruker Daltonics), a mixture that
contains Bradykin 1-7, Angiotensin II, Angiotensin I, Substance
P, Bombesin, Renin Substrate, ACTH clip 1-17, ACTH clip
18-39, and Somatostatin 28. The 18 samples were measured
randomly in triplicate and a total of 54 individual spectra were
acquired.
Internal Calibration of FT-ICR-MS Data. Raw files obtained
from the FT-ICR-MS were used as input for homemade
software described elsewhere.22–24 Spectra were internally
calibrated using 5 omnipresent Actin peptide masses dispersed
within the measurement range: 1198.7054, 1515.7491, 1790.8919,
1954.0643, and 2215.0699. After internal calibration, the ac-
curacy of the measurements was assessed using 7 peptide
masses derived from tubulin, GAPDH and HSPA5: 1143.6351,
1566.7795, 1613.9024, 1701.9072, 1701.9072, 1756.9660, 1824.9863,
and 2007.8933. On the basis of these peptides, an average
accuracy of less than 1 ppm was obtained. The final matrix
contained all masses detected and their respective intensities,
in at least 3 independent measurements and with a signal-to-
noise (S/N) > 4 to avoid noise peaks.
Normalization of FT-ICR-MS Data. Normalization of the
measured intensities was achieved multiplying them by a
normalization factor. This factor was determined by the ratio
of average intensity of all samples to average intensity of the
sample to be normalized. After normalization, we inspected
the reproducibility for both technical and biological replicates
by calculating the coefficient of variance of the 63 peptide
masses detected in all samples. For technical replicates, the
average CV was 11% (range 7-15%), and, for biological
replicates, the CV was 26% (range 19-36%).
Selection of Differentially Expressed Peptides. Comparison
of normalized peptide intensities, including zero values, was
performed using a Wilcoxon test.24 In a first set of analysis,
peptide intensities at a specific culture time point (day 5, day
10, or day 19) were compared between nondifferentiating and
differentiating samples. In a second set of analysis, peptide
intensities were compared as a function of time during culture
for both nondifferentiating and differentiating conditions.
Peptide masses with a p-value < 0.001 and a p-value < 0.01
showing an absolute difference (present and absent) between
the compared conditions were identified as being differently
expressed.
Data Visualization. The geometrical mean of the normalized
intensities of all samples was calculated. Values of intensity
equal to 0 were regarded as Not a Number (NaN). The level of
expression of each peptide mass in every sample was deter-
mined relative to this geometric mean and logarithmically
transformed (on a base 2 scale). Deviation from the geometrical
mean was considered as differential expression, despite pos-
sible unaccountable bias introduced by the MALDI ionization
process and the analyte interaction with the matrix used. To
minimize the latter possibility, we have measured all samples
in triplicate, observing acceptable CVs (7-15%) in contrast to
other equipments, like the MALDI-TOF, where CVs can be as
high as 30%. Similarity between samples, plotted by Pearson’s
correlation, was done using Omniviz (OmniViz, Maynard, MA,
version 5.0).
Immunodetection. Cell culture and protein isolation for
Western blotting experiments were identical to those described
above. Equal amounts of protein per sample were loaded and
separated by SDS-PAGE (10% Ready Gel Precast Gels, Bio-Rad,
Hercules, CA) and transferred onto a nitrocellulose membrane
(Hybond-ECL, Amersham Biosciences, Buckinghamshire, U.K.).
After blocking nonspecific signal with 4% fat free milk in Tris-
buffered saline (TBS), the membrane was incubated with
specific antibodies against fibronectin (mouse monoclonal to
FN1; 1:5000, Ab-11, Clone FBN11, NeoMarkers, Cat. MS-1351),
annexin A2 (rabbit polyclonal to ANXA2; 1 µg/mL, Abcam, Cat.
Ab41803), and GAPDH (loading control; mouse monoclonal;
1:20 000, Millipore, Cat. MAB374). Membranes were probed
with secondary antibodies, goat anti-mouse or goat anti-rabbit
IgG, conjugated with Alexa Fluor 680 (1:5000, Invitrogen, Cat.
A21057) or with IRDye 800CW (1:5000, LI-COR, Cat. 926-32211),
respectively. Immunoreactive bands were visualized using the
LI-COR Infrared Imaging System according to the manufac-
turer’s instructions (Odyssey Lincoln, NE).
FN1 expression was visualized by immunocytochemistry.
Nondifferentiating and differentiating cells were cultured in
similar conditions used for the MS analysis. After fixation in
10% formalin and blocking in PBS/2% BSA, cells were incubated
with mouse monoclonal FN1 antibody (1:100, Ab-11, Clone
FBN11, NeoMarkers, Cat. MS-1351). Next, slides were incubated
with secondary antibody, goat anti-mouse IgG conjugated with
Alexa Fluor 680 (1:300, Invitrogen, Cat. A21057). Slides were
washed 3 times in PBS/0.2% BSA, one time in PBS, one time
in 70% ethanol, and finally in 100% ethanol. After washing, they
were mounted in VectaShield containing DAPI (Vector Labo-
ratories, Burlingame, CA). As negative control, cells were not
incubated with primary antibody.
Results
ALP Activity and Mineralization of Human Preosteoblasts.
In this study, human preosteoblasts (SV-HFO) were used, which
can be stimulated to differentiate into mature osteoblasts that
produce a collagenous ECM that subsequently accumulates
mineral. Measuring parameters such as ALP activity and
calcium deposition over time can monitor this process. As
shown in Figure 1A, differentiating osteoblasts exhibited an
increase in ALP activity with a peak around day 10. The ALP
increase was followed by a rapid deposition of calcium (Figure
1B). This in vitro bone formation model is an excellent model
to study protein expression within the different stages of
osteoblast differentiation.
Qualitative LC-MS/MS Proteome Analysis: Proteins
Identified in Differentiating Human Osteoblast Cultures. To
identify as many as possible proteins, we combined chromato-
graphic techniques upstream to detailed MS measurements
(nano-LC-MS/MS). We have used the capabilities of this
technique to get qualitative insights into the proteins expressed
by differentiating osteoblasts combining data from days 5, 10,
and 19. This resulted in the successful identification of 381
proteins (Supplementary Table 1). To categorize the identified
osteoblast proteins, we performed gene ontology (GO) annota-
tion overrepresentation analyses. The proteins were categorized
for their annotation related to Biological Process (BP), Molec-
ular Function (MF), and Cellular Compartment (CC). Figure
2A depicts the significant top GO term categorization by
overrepresentation. Several overrepresented terms were related
to cytoskeleton such as structural constituent of the cytoskel-
eton (GO:0005200), actin cytoskeleton (GO:00015629), and actin
filament-based process (GO:0030029). Pyrophosphatase activity
(GO:0016462) proteins were overrepresented, as well as proteins
involved in other distinct processes like energy metabolism
(GO:0006096) or antigen processing and presentation (GO:
0042612; GO:0002474). In addition, the proteins were also
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categorized in protein families (Figure 2B). Enzymes were the
second biggest group of proteins (85 proteins) followed by
transporters (18). Phosphatases and ion channels (5 proteins
each) were also detected and represent an interesting group
of proteins for the process under study, where phosphate and
calcium ions represent the foundations for ECMmineralization.
We further inspected for proteins identified and GO annota-
tions that are established players in osteoblast differentiation
(Table 1). We have identified 5 proteins linked to skeletal system
development, several ECM components including collagens
and collagen binding proteins, and proteins that bind to
integrins, which are important for ECM-cell signal transduction
and osteoblast function (reviewed by Damsky et al., 1999).
Other osteoblast-relevant categories included proteins pos-
sessing pyrophosphatase activity and calcium ion binding
proteins with 41 and 29 proteins, respectively.
Quantitative MALDI-FT-ICR-MS Proteome Analysis:
Differentially Expressed Proteins in Mineralization Period.
Following the qualitative analysis, we used MALDI-FT-ICR-MS
to gather quantitative protein expression profiles. A total of 54
individual spectra were obtained corresponding to the day 5,
10, and 19 of differentiating and nondifferentiating conditions,
analyzed in 3 biological and 3 technical replicates. Data was
used as input for homemade software24 in order to generate a
data file containing all information regarding to peptide masses
detected and their respective intensities. For each spectrum,
we obtained 1688-2204 monoisotopic masses. The exception
was one spectrum, a technical replicate of a sample from day
10 nondifferentiating condition, that showed only 814 masses
and which was excluded from further analysis. Upon perform-
ing internal calibration, we obtained an average accuracy below
1 ppm in agreement with previous reports using similar
equipment.26,27 We compared all samples according to the
criteria mentioned in the Material and Methods (Selection of
Differentially Expressed Peptides) and identified 422 peptide
masses as significantly differentially expressed. Correlation
analysis based on measured intensities of these 422 peptide
masses is shown in Figure 3. It is interesting that this unbiased
approach delivered a correlation plot with a divergence of the
differentiating and nondifferentiating conditions. Within the
differentiating condition, there was also a clear discrepancy
between the premineralization andmineralization periods, with
a very strong correlation between the samples of the miner-
alization period (Figure 3). In addition, technical and biological
replicates always clustered together demonstrating the robust-
ness of the MALDI-FT-ICR-MS measurements.
These observations prompted us to examine in more detail
the protein expression differences within the differentiating
condition, comparing mineralization (day 19) versus the pre-
ceding premineralization period (days 5 and 10). Additionally,
we included in these analyses the two extreme phenotypes, that
is, day 19 in differentiating and nondifferentiating condition.
In total, these comparisons led to an identification of 52
differently expressed proteins (Table 2), according to the criteria
to combine MALDI-FT-ICR-MS and LC-MS/MS data men-
tioned in the Materials and Methods. Among other proteins,
cytoskeleton (actins, tubulins, and vimentin), actin binding
(CCT2, CSRP1, FLNA, MYH9, and VCL), ECM (FN1, LGALS1),
and calcium binding proteins (ANXA2, ANXA1) were identified.
Validation of Protein Expression and MS-Based
Quantification. We verified that most of the (FT-ICR-MS)
quantified peptides, mapping to the same protein, have similar
expression patterns (Figure 4A). To validate the MS data, we
selected two differentially expressed proteins that have been
reported to be relevant for bone biology, ANXA2 and FN1. The
expression pattern of these proteins was similar for both FT-
ICR-MS and Western blotting (Figure 4A,B). We have also
performed immunocytochemistry for FN1. As expected, FN1
immunocytochemistry from mineralized day 19 osteoblasts
disclosed a clear extracellular localization of this protein (Figure
4C).
Discussion
In vitro Human osteoblast differentiation models can be an
effective model to detect proteins that have pivotal roles in
bone formation and potential targets to shift bone remodeling
toward the anabolic process. The introduction of mass spec-
trometry into the proteomics field has made this type of
analysis feasible, revealing large set of proteins that can be
analyzed using bioinformatics tools to discover protein as-
sociations or overrepresented biological processes.
In the present work, we aimed to identify and quantify
proteins in an effort to gain knowledge about the osteoblast
differentiation process and identify novel proteins that may
modulate osteoblast mineralization. To this end, we exploited
our very well characterized human preosteoblast cell model5,15
and mass spectrometric analyses to identify proteins against
the background of osteoblast differentiation and in vitro bone
formation. Furthermore, we aimed to assess quantitative
differences both between differentiated mineralized cultures
and their nondifferentiated counterparts, as well as between
the premineralization and mineralization periods of the dif-
ferentiated osteoblast culture.
Figure 1. (A) Alkaline phosphatase activity and (B) calcium
deposition in the matrix corrected for cell number (as determined
by DNA measurement) in nondifferentiating and differentiating
human osteoblast cultures. Insets with Alizarin Red staining at
the final time point (day 19) are also shown.
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With regard to the protein profile of differentiating osteo-
blasts, we have identified 381 proteins. GO analysis revealed
that cytoskeleton and cytoskeletal related processes were
among the highest overrepresented terms. This shows the
importance of specific cytoskeleton assembly for osteoblast
differentiation, also verified by Higuchi and co-workers.28 It is
known that actin filaments (stress fibers) are physically linked
to the ECM by integrins.28–30 These transmembrane glycopro-
teins can interact with ECM proteins bridging the extracellular
with the intracellular compartment. This interaction affects the
organization of the cytoskeleton,31 signal transduction, and the
expression of transcription factors and osteoblast-specific genes
in osteoblasts.32,33 Other identified processes include distinct
processes such as glucose metabolism and antigen presenta-
tion. New insights linking bone remodeling to energy metabo-
lism control are described in the review by Rosen et al.34 The
Figure 2. (A) Gene Ontology of the significantly overrepresented terms in differentiating osteoblasts (Bonferroni p-value < 0.001). Only
the 10 highest overrepresented terms for biological process, molecular function and cellular compartment categories are shown. Numbers
next to the bars indicate overrepresentation level and numbers embedded in the bars indicate the proteins identified by MS/MS for
each category. (B) Pie chart representing the functional group distribution of the 381 identified proteins in differentiating osteoblast
cultures.
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fact that these processes were overrepresented can be related
to the fact that ECM synthesis, maturation, and mineralization
are highly demanding processes,35 leading to mitochondrial
and antioxidant enzyme changes.36
Interestingly, our data show a high overrepresentation of
proteins belonging to the MHC class I protein complex involved
in antigen presentation. Already back in 1989, Skjødt and co-
workers37 reported that osteoblast-like cells function as antigen
presenting cells, being able to stimulate peripheral bone
marrow cells (PBMCs). Since osteoclasts are derived from
PBMCs, it is tempting to speculate that overrepresentation of
this type of proteins may be related to the osteoblast effective-
ness to stimulate osteoclast differentiation from their precursors
or to interact with hematopoietic stem cells in the stem cell
niche.38
Phosphatases and ion channels constitute another group
of proteins identified. Some of these proteins have been
identified already as important players during osteoblast
differentiation. This is the case for the nuclear transmem-
brane ion channel protein, chloride intracellular channel 1
(CLIC1). Knockdown of CLIC1 suppresses osteoblast dif-
ferentiation from MSCs, whereas protein overexpression
increases osteogenic markers such as ALP activity.39 Other
interesting proteins include the voltage-dependent anion
channel 1, 2, and 3 (VDAC1, VDAC2, and VDAC3). These
membrane proteins play a role in the efflux of metabolites
including ATP and phosphate in the mitochondria.40 Inter-
estingly, these proteins are recurrently identified in matrix
vesicles (MV),14,41 the organelles implicated in initiation of
mineralization.41,43 Start of mineral deposition occurs by
accommodating the proper environment for crystal growth
in the MV. This implicates mobilization of calcium and
phosphate to form hydroxyapatite. Phosphate mobilization
can be achieved by degradation of pyrophosphate (PPi), a
mineralization inhibitor, into free phosphate (Pi). Our data
show that enzymes involved in this process were over-
represented by more than 2-fold (GO:0016462 pyrophos-
phatase activity, Figure 2A) supporting its importance for
osteoblast-mediated ECM mineralization.
In our quantitative MALDI-FT-ICR-MS approach, we
identified 52 differentially expressed proteins between day
19 mineralized and day 19 nonmineralized osteoblasts and
Table 1. Gene Ontology Terms Reporting Processes/Functions/Locations Connoted with Osteoblast Function
GO category term protein no.a geneb IPIc
Skeletal System Development (GO:0001501) 5
Annexin A2 ANXA2 IPI00418169
Collagen, type I, alpha 1 COL1A1 IPI00297646
Glycoprotein NMB GPNMB IPI00001592
Neurofibromin 1 NF1 IPI00220513
Peroxiredoxin 1 PRDX1 IPI00000874
Extracellular matrix (GO:0031012) 12
Collagen, type I, alpha 1 COL1A1 IPI00297646
Collagen, type VI, alpha 3 COL6A3 IPI00022200
Fibronectin 1 FN1 IPI00022418
Galectin 1 LGALS1 IPI00219219
Superoxide dismutase 1 SOD1 IPI00218733
Calcium ion binding (GO:0005509) 29
Annexin A1 ANXA1 IPI00218918
Calnexin CANX IPI00020984
Myeloid cell leukemia sequence 1 MCL1 IPI00030356
Protein disulfide isomerase family A, member 4 PDIA4 IPI00009904
Signal sequence receptor, delta SSR4 IPI00019385
Pyrophosphatase activity (GO:0016462) 41
ATP synthase, H+ transporting, mitochondrial f1 complex, alpha
subunit 1
ATP5A1 IPI00440493
Dynein, axonemal, heavy chain 7 DNAH7 IPI00180384
Eukaryotic translation elongation factor 1 alpha 1 EEF1A1 IPI00025447
MDN1, midasin homologue (yeast) MDN1 IPI00167941
X-ray repair complementing defective repair in chinese hamster cells
5
XRCC5 IPI00220834
Collagen binding (GO:0005518) 4
CD44 molecule CD44 IPI00297160
Fibronectin 1 FN1 IPI00022418
Serpin peptidase inhibitor, clade H, member 1 SERPINH1 IPI00032140
Thrombospondin 1 THBS1 IPI00296099
Integrin binding (GO:0005178) 5
Actinin, alpha 1 ACTN1 IPI00013508
Actinin, alpha 4 ACTN4 IPI00013808
Calreticulin CALR IPI00020599
Glycoprotein NMB GPNMB IPI00001592
Thrombospondin 1 THBS1 IPI00296099
Ion channel activity (GO:0005216) 5
Voltage-dependent anion channel 1 VDAC1 IPI00216308
Voltage-dependent anion channel 2 VDAC2 IPI00024145
Voltage-dependent anion channel 3 VDAC3 IPI00031804
Transient receptor potential cation channel, subfamily M, member 1 TRPM1 IPI00385124
Chloride intracellular channel 1 CLIC1 IPI00010896
a Number of total proteins in the group. b Official gene symbol. c IPI accession number.
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between day 19 mineralized and the osteoblast preminer-
alization time points, day 5 and day 10. Some of these
proteins will be discussed in more detail. We found that
cytoskeleton components (several actins, tubulins, and vi-
mentin) and actin binding proteins (CCT2, CSRP1, FLNA,
MYH9, and VCL) were differentially expressed in differentiat-
ing osteoblasts. This follows the data discussed above and
further substantiates a prominent role for cytoskeletal
reorganization in osteoblast differentiation. ECM (FN1,
LGALS1) and calcium binding (ANXA2, ANXA1) proteins were
also identified among differentially expressed proteins. FN1
is an abundant ECM glycoprotein with significantly higher
Figure 3. Pearson correlation plot of the 422 significant differentially expressed peptide masses as determined by FT-ICR-MS
measurements. All samples, from both differentiating and nondifferentiating osteoblasts, are plotted against each other to determine
their degree of similarity based on the determined quantitative peptide profile. Lines and geometric shapes: black, nondifferentiating
condition; yellow and orange, differentiating condition, premineralization and mineralization period, respectively. Geometric shapes:
circles, day 19; squares, day 10; pentagons, day 5; filled, empty and striped shapes represent the 3 biological replicates, measured
each in 3 technical replicates (with exception to a technical replicate from day 10 nondifferentiating condition that was excluded
from the analysis); Red, high similarity; blue, low similarity.
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expression, at all time points analyzed, in differentiating
osteoblasts relative to their nondifferentiated counterparts
(Figure 4A,B). FN1 is required for osteoblast differentiation
and mineralization through interaction with the integrin
R51 FN1 receptor.44 Besides determining osteoblast cellular
fate, FN1 is also required for their survival once osteoblasts
are mature.45 We identified ANXA2 as a protein that was
enhanced during stages of premineralization. Other studies
showed that osteoblasts overexpressing ANXA2 show en-
hanced mineralization.46 ANXA2 is a calcium-dependent
phospholipid binding protein located in the ECM and in
MV14,43 where they are thought to be important for Ca2+
uptake.47 The fact that we observed the highest expression
of ANXA2 in the premineralization phase might be associated
with increasing ALP activity verified at this stage and the
start of Ca2+ uptake into the MV. Interestingly, ANXA2 has
been shown to be an autocrine factor for osteoclasts,
increasing osteoclastogenesis and resorption.48,49 Here we
show that ANXA2 was also expressed and regulated during
osteoblast differentiation making it tempting to speculate
about implications in the osteoblast-osteoclast crosstalk.
LMNA belongs to the nuclear inner membrane class of
proteins. Mutations in this gene display a phenotype compat-
ible with progeria syndrome exhibiting loss of subcutaneous
fat, muscular dystrophy, and an osteoporotic phenotype.22 The
bone phenotype is thought to be due to a deficit in osteoblast
and matrix formation.50,51 Our data supports the importance
of this protein for osteoblast differentiation, with higher expres-
sion in differentiating cells. However, while ANXA2 and FN1
levels were higher prior to mineralization, LMNA expression
peaked when cells were mature. This difference in expression
pattern is probably related to the physiological changes of the
osteoblast in its progression toward osteocyte. Thus, these
proteins seem to represent hallmarks of the period of osteoblast
development, ANXA2 and FN1 of the premineralization, and
LMNA of the mineralization period.
Also proteins were specifically suppressed in late staged
differentiating osteoblasts, including PLOD2, NTE5, and
Figure 4. (A) Quantitative FT-ICR-MS profile obtained for FN1 and ANXA2. Two peptides belonging to each of these proteins are shown.
(B) Immunodetection of FN1, ANXA2, and GAPDH (loading control). Fluorescence detection was done using the LI-COR system. Numbers
were calculated using the band intensities and indicate protein expression relative to GAPDH. (C) Immunocytochemistry for FN1 in
SV-HFO cells from day 19 mineralizing condition. Negative control shown as inset.
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LGALS1. PLOD2 forms hydroxylysine residues in -Xaa-Lys-
Gly- sequences in collagens that serve as sites of attachment
for carbohydrate units being essential for the stability of the
intermolecular collagen cross-links. Mutations in PLOD2
cause Bruck Syndrome in which the bone collagen lacks
pyridinolines and the other cross-links based on hydroxyl-
ysine aldehydes.52 NTE5, more often referred to as CD73, is
a glycosyl phosphatidylinositol (GPI) plasma membrane
anchored enzyme,53 regarded as a MSC marker.54,55 LGALS1
is a -galactoside-binding protein that has been implicated
in several processes from cell adhesion and migration56 to
proliferation57 and apoptosis.58 Human fetal MSCs upon
exposure to LGALS1 enter myogenic differentiation.59 Down-
regulation of PLOD2 upon mineralization is perhaps an
indication that collagen cross-linking regulation is mostly
needed in the premineralization stage, when ECM is actively
synthesized. NTE5 and LGALS1 decreased expression might
be a sign of cellular maturity toward fully differentiated
osteoblasts.
Like any other approach, the use of the MALDI-FT-ICR-
MS for label-free quantitation has its own advantages and
disadvantages. Among the latter is the need to use an
independent platform to identify the peptides/proteins
profiled, due to the inability to generate good fragmentation
data on single charged MALDI ions in FTMS by collision-
induced dissociation.60 On the other hand, MALDI-FT-ICR-
MS data does not require extensive data processing and
analysis. Other advantages include the high sensitivity and
high mass resolution described elsewhere,60–62 and the
superior reproducibility of these MS measurements, crucial
in quantitative proteomics. Variation of peptide intensity
measurements was as low as 15% in technical replicates and
36% considering biological replicates. For the majority of the
different peptides detected that belong to the same protein,
the FT-ICR-MS determined expression patterns were similar.
Moreover, immunodetection of FN1 and ANXA2 confirmed
their up-regulation in differentiated osteoblasts compared
to their nondifferentiating counterparts.
From the list of proteins generated, it is evident that classical
osteoblast markers such as RUNX2, ALPL, SPP1, BGLAP, and
SPARC were not observed. We believe that this was due to the
fact that their concentrations were low and beyond the range
we could detect. In human cells, the range of protein copy
numbers is 7-8 orders of magnitude,63 while MS analysis can
only cover up to 4-6.64 To tackle this problem, we believe that
the approach here described should be combined with the
isolation of subcellular and ECM proteomes.
This study aimed to contribute to the knowledge of the
osteoblast differentiation program by an unbiased mass
spectrometry-based proteomics approach. Qualitative analy-
sis revealed not only proteins expressed by differentiating
osteoblasts, but also biological processes and molecular
functions that drive cells toward bone formation and min-
eralization. At this level, cytoskeleton, energy metabolism,
and antigen presentation processes were among the most
overrepresented categories. Complementation of the analysis
with quantitative differences revealed both bone related
proteins, with characteristic expression patterns in the course
of differentiation (ANXA2, FN1, and LMNA), and other
proteins (e.g., LGALS1) not extensively studied in the bone
field. The identification of proteins having a proven role in
bone function in addition to others with yet unknown bone
function strongly supports that the latter are also important
for osteoblast differentiation and mineralization. Altogether,
our data provides more information in the pursuit of targets
for bone formation modulation, which is of utmost impor-
tance to develop new therapies for bone related diseases
such as osteoporosis.
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